Share price · UTHR
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when UTHR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 1 Oct 2026+5.4%
- 30 Sep 2026+12.5%
- 24 Sep 2026-3.5%
Nothing announced by UTHR that day or the session before.
- 2 Sep 2026-4.0%
Nothing announced by UTHR that day or the session before.
- 30 Mar 2026+12.5%
- 9 Mar 2026+10.7%
- 26 Feb 2026-5.9%
- 25 Feb 2026+13.0%
Share of unusual movement by asset
For each asset, the share of UTHR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(7 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | GD2Monoclonal antibody | Neuroblastoma | |
Tadalafil(Adcirca) | Approved | PDE5Small molecule | Pulmonary Arterial Hypertension |
| Approved | IP receptor (prostacyclin pathway)Small molecule | Pulmonary Arterial Hypertension | |
| Approved | IP receptor (prostacyclin pathway)Small molecule | Pulmonary Arterial Hypertension | |
| Approved | IP receptor (prostacyclin pathway)Small molecule | Idiopathic Pulmonary FibrosisPulmonary Arterial HypertensionPulmonary Hypertension Associated with Interstitial Lung Disease | |
| Approved | IP receptor (prostacyclin pathway)Small molecule | Idiopathic Pulmonary FibrosisPulmonary Arterial HypertensionPulmonary Hypertension Associated with Interstitial Lung Disease | |
| Phase 3 | IP receptor (prostacyclin pathway)Small molecule | Pulmonary Arterial Hypertension |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
2027 (1)
November 2027 (1)
What to watch
2028 (1)
May 2028 (1)
What to watch
2029 (1)
December 2029 (1)
What to watch
2034 (1)
September 2034 (1)
What to watch
Regulatory and conference events
(6)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $833M | $279M | $1.2B+ $879M short-term inv. | —$307M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $783M | $146M | $1.8B+ $859M short-term inv. | —$314M operating cash flow | report ↗ |
| 2026-Q1 | $782M | $138M | $1.3B+ $874M short-term inv. | —$463M operating cash flow | report ↗ |
| 2025-Q3 | $800M | $128M | $1.3B+ $1.4B short-term inv. | —$562M operating cash flow | report ↗ |
| 2025-Q2 | $799M | $134M | $1.6B+ $1.5B short-term inv. | —$192M operating cash flow | report ↗ |
| 2025-Q1 | $794M | $149M | $1.9B+ $1.4B short-term inv. | —$461M operating cash flow | report ↗ |
| 2024-Q3 | $749M | $104M | $1.6B+ $1.8B short-term inv. | —$377M operating cash flow | report ↗ |
| 2024-Q2 | $715M | $140M | $1.4B+ $1.6B short-term inv. | —$232M operating cash flow | report ↗ |
| 2024-Q1 | $678M | $104M | $1.3B+ $1.5B short-term inv. | —$377M operating cash flow | report ↗ |
| 2023-Q3 | $609M | $85M | $1.1B+ $1.8B short-term inv. | —$346M operating cash flow | report ↗ |
| 2023-Q2 | $597M | $89M | $1.1B+ $1.6B short-term inv. | —$106M operating cash flow | report ↗ |
| 2023-Q1 | $507M | $83M | $1.2B+ $1.7B short-term inv. | —$375M operating cash flow | report ↗ |
| 2022-Q3 | $516M | $66M | $967M+ $1.6B short-term inv. | —$259M operating cash flow | report ↗ |
| 2022-Q2 | $467M | $94M | $795M+ $1.5B short-term inv. | —$127M operating cash flow | report ↗ |
| 2022-Q1 | $462M | $69M | $813M+ $1.5B short-term inv. | —$289M operating cash flow | report ↗ |
| 2021-Q3 | $445M | $79M | $909M+ $1.1B short-term inv. | —$186M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $3.2B | $550M | $1.6B+ $1.4B short-term inv. | —$1.6B operating cash flow | report ↗ |
United Therapeutics reported fiscal 2025 revenue of $3,182.7M, up 10.6% YoY from $2,877.4M, and R&D spend of $550M, up 14.3% YoY from $481M. Cash and equivalents stood at $1,557.1M, with net income of $1,334.7M for the period.
The company highlighted clinical progress, including the TETON 2 phase 3 study of Nebulized Tyvaso in idiopathic pulmonary fibrosis meeting its primary endpoint, with TETON 1 data expected late in the first quarter or early in the second quarter of 2026. Enrollment in the phase 3 ADVANCE OUTCOMES study of ralinepag concluded in June 2025, with topline data also expected around that time. In xenotransplantation, the FDA cleared the EXPAND study IND and the first UKidney transplant occurred in the fourth quarter of 2025, while the EXTEND study IND was cleared in August 2025.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $2.9B | $481M | $1.7B+ $1.6B short-term inv. | —$1.3B operating cash flow | report ↗ |
| 2023-FY | $2.3B | $408M | $1.2B+ $1.8B short-term inv. | —$978M operating cash flow | report ↗ |
| 2022-FY | $1.9B | $323M | $961M+ $1.9B short-term inv. | —$803M operating cash flow | report ↗ |
| 2021-FY | $1.7B | $540M | $895M+ $1.0B short-term inv. | —$598M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($864K), 2939 sales ($1.4B). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-19 | MAHON PAUL A · EVP & GENERAL COUNSEL | Option exercise | 8,300 | $146.03 | $1.2M | Form 4 |
| 2026-11-19 | MAHON PAUL A · EVP & GENERAL COUNSEL | Open-market sale | 440 | $554.73 | $244K | Form 4 |
| 2026-11-19 | MAHON PAUL A · EVP & GENERAL COUNSEL | Open-market sale | 1,240 | $556.07 | $690K | Form 4 |
| 2026-11-19 | MAHON PAUL A · EVP & GENERAL COUNSEL | Open-market sale | 523 | $557.46 | $292K | Form 4 |
| 2026-11-19 | MAHON PAUL A · EVP & GENERAL COUNSEL | Open-market sale | 378 | $558.49 | $211K | Form 4 |
| 2026-11-19 | MAHON PAUL A · EVP & GENERAL COUNSEL | Open-market sale | 400 | $559.50 | $224K | Form 4 |
| 2026-11-19 | MAHON PAUL A · EVP & GENERAL COUNSEL | Open-market sale | 197 | $560.63 | $110K | Form 4 |
| 2026-11-19 | MAHON PAUL A · EVP & GENERAL COUNSEL | Open-market sale | 300 | $561.78 | $169K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 838 reporting institutions held 41.5M shares ($23.3B, 97.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 5,399,649 | $3.2B |
| 2 | Avoro Capital Advisors LLC | 2,630,000 | $1.6B |
| 3 | WELLINGTON MANAGEMENT GROUP LLP | 2,264,247 | $1.3B |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2,003,742 | $1.2B |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 1,957,539 | $1.2B |
| 6 | STATE STREET CORP | 1,843,963 | $1.1B |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 1,787,019 | $1.1B |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1,233,029 | $729.9M |
| 9 | JANUS HENDERSON GROUP PLC | 866,930 | $514.0M |
| 10 | AQR CAPITAL MANAGEMENT LLC | 826,226 | $486.4M |
| 11 | ASSETMARK, INC | 616,050 | $365.3M |
| 12 | Invesco Ltd. | 608,367 | $360.7M |
| 13 | FMR LLC | 528,346 | $313.3M |
| 14 | DIMENSIONAL FUND ADVISORS LP | 512,739 | $304.0M |
| 15 | DEERFIELD MANAGEMENT COMPANY, L.P. | 457,000 | $271.0M |